Codexis, Inc. (CDXS)

Codexis, Inc. (CDXS) stock has experienced a significant decline in the past six months, decreasing by 68.29% from January 6, 2025, to January 5, 2026. As of November 1, 2025, the stock was down 32% over the preceding year, but it saw a gain of 5.52% on January 6, 2026. Key events include the Q3 2025 financial results, which reported a revenue decline of 32.8% from Q3 2024 due to customer manufacturing schedules. Codexis announced a lease for a GMP Manufacturing Facility on November 10, 2025. The company was featured in CBS's Economy 4.0 Docuseries on December 4, 2025, highlighting its RNA manufacturing innovation. An evaluation agreement with Axolabs to evaluate its ECO Synthesis® Manufacturing Platform for oligonucleotide therapeutics was announced on January 7, 2026.

Demand for Codexis, Inc.'s products and services exhibits variability, with customer manufacturing schedules and the timing of clinical trials driving quarter-to-quarter revenue volatility. Demand is not consistent throughout the year and can fluctuate based on client project timelines.

Codexis, Inc. is a protein engineering company providing enzymatic solutions for pharmaceuticals, fine chemicals, biotherapeutics, food and beverage, and agriculture, operating in the Healthcare sector, specifically Biotechnology and Life Sciences Tools and Services. The company uses its CodeEvolver® technology platform to discover, develop, and enhance novel, high-performance enzymes and other proteins. Its major products include biocatalysts and pharmaceutical intermediates designed to improve efficiency in pharmaceutical manufacturing. The ECO Synthesis™ Manufacturing Platform is a proprietary enzymatic route for manufacturing RNA-based therapeutics. Screening Kits and Codex HiFi Hot Start DNA Polymerase are products for life science and diagnostic applications. An early-stage enzyme therapeutic is being developed for treating phenylketonuria (PKU) in partnership with Nestle HealthScience.

Codexis, Inc. has a global presence across the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China, deriving its maximum revenue from the Americas.

Codexis' brand reputation has likely been affected by its significant stock price decline, with shareholders experiencing losses. The company's stock underperformed both the US Life Sciences industry and the broader US Market. Being featured in CBS's Economy 4.0 Docuseries, highlighting its RNA manufacturing innovation, could positively contribute to its reputation. The company's strategic shift towards higher-margin technologies and partnerships with companies like Merck and Pfizer are aimed at driving future growth and could enhance its standing.

Codexis, Inc. is primarily owned by institutional shareholders, who hold between 73.04% and 78.54% of the company's stock. Insiders also hold a significant stake. Major institutional owners include Opaleye Management Inc., BlackRock, Inc., and Vanguard Group Inc. Vivo Ventures VII LLC is the largest individual shareholder, owning 17.89% of the company.